Welcome to our dedicated page for Cencora SEC filings (Ticker: COR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cencora, Inc. filings document material events for a NYSE-listed pharmaceutical distribution and healthcare solutions company. Recent 8-K disclosures furnish quarterly operating results, Regulation FD information, executive officer transition details, annual meeting voting results and entries into material definitive agreements.
The company’s regulatory record also covers capital-structure matters, including common stock and listed senior notes, registered public debt offerings and the terms of multiple senior note maturities. Governance filings describe director elections and other shareholder voting matters, while material-event reports connect financing activity and completed acquisitions to the company’s operating and financial disclosures.
Cencora, Inc. reports higher results for the quarter ended December 31, 2025, with revenue of $85.9 billion, up 5.5% year over year, and net income of $566.1 million. Diluted earnings per share were $2.87, compared with $2.50 a year earlier.
Growth was driven mainly by the U.S. Healthcare Solutions segment, where revenue rose 5.0% and gross profit increased 29.5%, helped by the January 2025 acquisition of Retina Consultants of America and strong specialty and GLP‑1 product sales. International Healthcare Solutions revenue grew 9.6%, led by European distribution.
Operating income rose 7.7% to $760.4 million, despite a $249.5 million impairment tied to the U.S. Consulting Services business held for sale. Results benefited from an $86.8 million litigation credit from a derivative lawsuit settlement and a higher LIFO credit of $77.6 million. Cash used in operating activities was $2.3 billion, largely from higher inventories and receivables, while total debt was $7.9 billion. The company also highlights a $4.6 billion cash acquisition of OneOncology completed in February 2026, funded with new debt.
Cencora, Inc. reported quarterly results for the fiscal quarter ended December 31, 2025 via a news release furnished as an exhibit, and is holding a conference call and webcast to discuss these results and related matters.
The company also acquired the majority of the outstanding equity interests it did not previously own in OneOncology, a national oncology-focused physician platform, for total cash consideration of approximately $4.6 billion, funded through new debt financing. OneOncology’s affiliated practices and management retained a minority interest, and OneOncology’s future operating results will be included in Cencora’s U.S. Healthcare Solutions segment.
Cencora, Inc. director Ellen G. Cooper filed an initial ownership report on Form 3 stating that she currently holds no securities of Cencora. The filing confirms her status as a director and formally records that she has no beneficial ownership of the company’s securities at this time.
Cencora, Inc. President & CEO Robert P. Mauch reported an option exercise and share sale. On January 20, 2026, he exercised a non-qualified stock option for 3,763 shares of Cencora common stock at an exercise price of $86.09 per share. On the same date, he sold 5,096 shares of common stock at a price of $354.73 per share. After these transactions, he directly owned 66,726 shares of Cencora common stock and held 3,762 stock options linked to common shares. The option referenced in the filing became exercisable in four equal installments from November 13, 2020 through November 13, 2023.
Cencora is asking shareholders to vote at its virtual 2026 annual meeting on March 5, 2026 to elect 11 directors, approve fiscal 2025 executive pay on an advisory basis, and ratify Ernst & Young LLP as auditor for fiscal 2026. The company reports fiscal 2025 revenue of $321.3 billion and total shareholder return of 40%, and says it returned nearly $900 million through dividends and share repurchases.
Cencora highlights progress on its pharmaceutical‑centric strategy, including acquiring Retina Consultants of America and announcing plans to invest $1.0 billion through 2030 to strengthen its U.S. distribution network. Board refresh and governance are central themes: 10 of 11 nominees are independent, eight have joined in the past five years, and D. Mark Durcan became independent Board Chair on October 1, 2025.
The proxy emphasizes board diversity, succession planning, and extensive shareholder engagement on topics such as the CEO transition to Robert P. Mauch, risk oversight, compensation design, and corporate responsibility. It also details committee structures overseeing capital allocation, executive pay, compliance, risk management, and controlled substances distribution.
Cencora, Inc. reported that its Board of Directors appointed Ellen G. Cooper as a director, effective January 20, 2026. To accommodate this change, the Board increased its size from ten to eleven members under the company’s Amended and Restated Bylaws.
Ms. Cooper will receive the same compensation and benefits as other non-employee directors under Cencora’s Compensation Policy for Non-Employee Directors, with all cash and equity amounts pro-rated from her appointment date through the company’s 2026 Annual Meeting of Stockholders. The company states there are no arrangements or understandings with other persons regarding her appointment, no family relationships with existing directors or executive officers, and no related-party transactions requiring disclosure. She has not yet been named to any Board committees.
Cencora also issued a news release on January 22, 2026 announcing the appointment, which is furnished as Exhibit 99.1 to this report.
Form 144 reports a planned insider sale of 5,096 common shares through Fidelity Brokerage Services LLC on the NYSE around 01/20/2026. The planned sale has an aggregate market value of 1,807,704.08 based on the filer’s calculation, compared with 193,993,444 common shares outstanding. The shares to be sold come from 1,333 shares acquired via restricted stock vesting on 11/09/2024 as compensation and 3,763 shares acquired on 01/20/2026 from options originally granted on 11/13/2019 and paid for in cash.
Over the prior three months, Robert Mauch has sold common shares of the same issuer in three transactions: 5,097 shares on 10/20/2025 for gross proceeds of 1,665,699.60, 5,096 shares on 11/18/2025 for 1,868,397.44, and 5,096 shares on 12/18/2025 for 1,750,221.20. The signer represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
Cencora, Inc. has expanded its financing capacity to support its planned acquisition of OneOncology. The company increased total commitments under its revolving credit facility by $1.0 billion to $5.5 billion, providing additional flexible liquidity.
Cencora also entered into a new senior unsecured term loan agreement totaling $1.5 billion, split into a $500 million tranche maturing two years after draw and a $1.0 billion tranche maturing three years after draw. In addition, the company arranged a separate $3.0 billion 364-day senior unsecured term loan. Proceeds from these loans will help fund the OneOncology purchase price, repay OneOncology’s existing debt, and cover related fees and expenses. Both facilities include leverage covenants generally capped at 4.00 to 1.00, which may temporarily increase to 4.50 to 1.00 when closing a material acquisition, and their funding is conditioned on consummation of the acquisition. These new facilities fully replace previously obtained $4.5 billion bridge financing commitments.
Cencora, Inc. Executive Vice President Silvana Battaglia reported acquiring company shares through an employee stock purchase program. On December 31, 2025, she acquired 27.344 shares of Cencora common stock at a price of $287.088 per share under the Employee Stock Purchase Plan, which is noted as exempt under Rule 16b-3(c) and Rule 16b-3(d). After this purchase, she beneficially owned 18,823.808 shares of common stock in direct ownership.